Neuromuscular Diseases  >>  sifalimumab (MDX-1103)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sifalimumab (MDX-1103) / AstraZeneca
NCT00533091: A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis

Checkmark For dermatomyositis and polymyositis
Dec 2013 - Dec 2013: For dermatomyositis and polymyositis
Checkmark
Feb 2013 - Feb 2013: 
Completed
1b
51
US
MEDI-545, Placebo
MedImmune LLC
DERMATOMYOSITIS OR POLYMYOSITIS
08/10
10/10

Download Options